Chordoma — Trials · CancerIndex

Clinical trials

Registered studies

58 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 7%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05286801	Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	active not recruiting	Phase 1 / Phase 2	86	National Cancer Institute (NCI)NIH	3	Jul 14, 2026	clinicaltrials
NCT06957327	A Study of ERAS-601 in People With Chordoma	active not recruiting	Phase 1 / Phase 2	12	Memorial Sloan Kettering Cancer CenterOTHER	1	Apr 28, 2026	clinicaltrials